Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C–Infected Patients With Compensated and Decompensated Cirrhosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|62|3|715-725

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.62, Iss.3, 2015-09, pp. : 715-725

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 79-86

John Wiley & Sons Inc

Access to resources Recommend Favorite

Relative efficacy and safety of simeprevir and telaprevir in treatment‐naïve hepatitis C‐infected patients in a Japanese population: A Bayesian network meta‐analysis

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 10, 2015-10 ,pp. : E89-E98

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of sofosbuvir for the treatment of chronic hepatitis C‐infected patients

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 11, 2015-11 ,pp. : 882-889

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of sofosbuvir for the treatment of chronic hepatitis C‐infected patients

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 1352-0504, Iss. 11, 2015-11 ,pp. : 882-889

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1004-1012

John Wiley & Sons Inc

Access to resources Recommend Favorite